S
Scott M. Grundy
Researcher at University of Texas Southwestern Medical Center
Publications - 849
Citations - 246629
Scott M. Grundy is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Cholesterol & Lipoprotein. The author has an hindex of 187, co-authored 841 publications receiving 231821 citations. Previous affiliations of Scott M. Grundy include University of California, San Francisco & University of California, Davis.
Papers
More filters
Journal ArticleDOI
Cholesterol and Coronary Heart Disease: Future Directions
TL;DR: For people with high cholesterol levels, dietary modification is undoubtedly the first step of management, but the fraction of people responding adequately to dietary change remains to be determined.
Journal ArticleDOI
Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.
Gloria Lena Vega,Scott M. Grundy +1 more
TL;DR: Benefits of normalization of LDL metabolism and marked reduction of triglycerides by gemfibrozil suggest benefit to hypertriglyceridemic patients who are at high risk for coronary heart disease, however, when LDL-cholesterol level rises excessively, gemfiberzil may not be sufficient therapy.
Journal ArticleDOI
The influence of age and body mass index on the metabolic syndrome and its components
TL;DR: Evaluated the influence of ageing and body mass index (BMI) on the revised National Cholesterol Education Program (NCEP)‐defined metabolic syndrome, its components, diabetes and coronary heart disease prevalence using the Third National Health and Nutrition Examination Survey.
Journal ArticleDOI
Metabolic Risk Susceptibility in Men Is Partially Related to Adiponectin/Leptin Ratio
Gloria Lena Vega,Scott M. Grundy +1 more
TL;DR: Men with high adiponectin/leptin ratios have better triglyceride profile and insulin sensitivity than men with a low ratio regardless of waist girth, and the ratio decreased progressively with the increase in the number of risk factors for metabolic syndrome.
Journal ArticleDOI
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
W. V. Brown,Carlos A. Dujovne,J. W. Farquhar,E. B. Feldman,Scott M. Grundy,Robert H. Knopp,N. L. Lasser,Margot J. Mellies,Robert H. Palmer,Paul Samuel +9 more
TL;DR: The results were similar to those obtained in European open trials of fenofibrate and were better than the lipid changes seen at comparable times in the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) cholestyramine study.